MedPath

Assessments of the effect of Salmeterol and Fluticasone Propionate (SFC250) on the patients with chronic obstructive pulmonary disease by Impulse Oscillometry

Not Applicable
Conditions
Chronic Obstructive Pulmonary Disease
Registration Number
JPRN-UMIN000004196
Lead Sponsor
St. Marianna University School of Medicine, Division of Respiratory and Infectious Diseases
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patient is receiving inhaled steroids and long-acting beta2-agonists. 2. Patient is diagnosis as asthma. 3. Patient is decided as inappropriate for this study by the investigator.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To assess the additive effects of SFC250 on pulmonary functions (IOS, etc) of COPD patients treated by tiotropium on 4, 8,12weeks
Secondary Outcome Measures
NameTimeMethod
a) Improvement of clinical symptoms (dyspnea, cough, sputum) and QOL b) Reduction of the exacerbations (follow up to 52weeks) c) Adverse events
© Copyright 2025. All Rights Reserved by MedPath